Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Rose Bengal-Based Drug Kills Both Primary and Secondary Melanoma Tumors

By BiotechDaily International staff writers
Posted on 02 Sep 2013
Drug developers have discovered the immunological mechanism that underlies the ability of the candidate drug PV-10 to induce regression of primary and secondary melanoma tumors.

PV-10, which was developed by Provectus Pharmaceuticals, Inc., (Knoxville, TN, USA) is a 10% solution of Rose Bengal formulated for IL (intralesional) injection. Rose Bengal is a water-soluble xanthene dye that had been previously employed in liver function studies and is still in use by ophthalmologists.

Investigators at the Moffitt Cancer Center (Tampa, FL, USA) worked with two different mouse models: BALB/c mice bearing MT-901 breast cancer and C57BL/6 mice that had been injected with B16 melanoma cells to establish one subcutaneous primary tumor and multiple secondary lung lesions.

Results published in the July 17, 2013, online edition of the journal PLOS ONE revealed that treatment of the subcutaneous lesion with a single injection of IL PV-10 led to regression of the injected lesion as well as the distant B16 melanoma lung metastases.

Splenocytes isolated from tumor bearing mice treated with IL PV-10 demonstrated enhanced tumor-specific IFN-gamma (interferon-gamma) production compared to splenocytes from saline-treated mice in both models. In addition, a significant increase in lysis of B16 cells by T-cells isolated after PV-10 treatment was observed. Transfer of T-cells isolated from tumor-bearing mice treated with IL PV-10 led to tumor regression in untreated mice bearing B16 melanoma.

The investigators concluded that these studies established that IL PV-10 therapy induced tumor-specific T-cell-mediated immunity, which supported the concept of combining IL PV-10 with immunotherapy for advanced malignancies. “Various injection therapies for melanoma have been examined over the past 40 years, but few have shown the promising results we are seeing with PV-10,” said senior author Dr. Shari Pilon-Thomas, assistant member of the immunology program at the Moffitt Cancer Center.

Related Links:
Provectus Pharmaceuticals, Inc.
Moffitt Cancer Center


Channels

Genomics/Proteomics

view channel
Image: Transmission electron micrograph of norovirus particles in feces (Photo courtesy of Wikimedia Commons).

Norovirus Interacts with Gut Bacteria to Establish a Persistent Infection That Can Be Blocked by Interferon Lambda

A team of molecular microbiologists and virologists has found that norovirus requires an intimate interaction with certain gut bacteria to establish a persistent infection, and that the infective process... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more

Business

view channel

Program Designed to Provide High-Performance Computing Cluster Systems for Bioinformatics Research

Dedicated Computing (Waukesha, WI, USA), a global technology company, reported that it will be participating in the Intel Cluster Ready program to deliver integrated high-performance computing cluster solutions to the life sciences market. Powered by Intel Xeon processors, Dedicated Computing is providing a range of... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.